EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Celastrol as a neuroprotective drug: current status and challenges

Xiao Wang, Wei Li, Xiaoli Liu, Jie Liang, Luoyang Wang, Guixian Liu, Yi Liu, Meiying Song, Zhen Li, Yuanzhen Guo, Shuai Li, Ningjing Fu und 1 weitere

International Immunopharmacology · 2026-01 · 168 · 115846

DOI: 10.1016/j.intimp.2025.115846 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-01. Verfasst von Xiao Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, PR China. Hauptthemen laut MEDLINE: Pentacyclic Triterpenes, Neuroprotective Agents, Neurodegenerative Diseases, Triterpenes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurological disorders are increasing worldwide, imposing a major social and economic burden. Therefore, there is an urgent need to explore effective treatment methods to alleviate neurological disorders. Celastrol, derived from the traditional Chinese medicine Tripterygium wilfordii Hook. f., has been shown in multiple studies to exhibit promising neuroprotective effects in neurodegenerative, including Parkinson's disease, Alzheimer's disease, and spinal cord injury. The targets or pathways through which celastrol exerts its neuroprotective effects are diverse. This paper primarily focuses on in vivo animal models (such as Parkinson's disease mouse models, Alzheimer's disease mouse models) and in vitro cell models (such as neuronal cell lines, primary cultured neurons) experiments to comprehensively summarize the molecular mechanisms underlying celastrol's neuroprotective effects. Celastrol exerts its neuroprotective effects through pathways such as reducing inflammation, activating the autophagy-lysosome pathway, and inhibiting ferroptosis. Additionally, we discuss the current challenges faced by celastrol and potential strategies to address them. Collectively, these findings highlight celastrol as a promising therapeutic candidate, although further pharmacokinetic optimization and clinical validation are essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pentacyclic TriterpenesNeuroprotective AgentsNeurodegenerative DiseasesTriterpenesAnimalsHumansDisease Models, AnimalAutophagyTripterygiumMice

Stichwörter der Autor:innen

CelastrolCentral nervous systemNeuroprotectionPeripheral nervous system

Substanzen

celastrolPentacyclic TriterpenesNeuroprotective AgentsTriterpenes

Autor:innen und Institutionen

  • Department of Immunology, School of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, PR China.
  • Department of Immunology, School of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, PR China. Electronic address: zhangbei124@aliyun.com.

Förderung

  • Natural Science Foundation of Shandong Province

Zitieren

APA

Wang, X., Li, W., Liu, X., Liang, J., Wang, L., Liu, G., Liu, Y., Song, M., Li, Z., Guo, Y., Li, S., Fu, N., & Zhang, B. (2026). Celastrol as a neuroprotective drug: current status and challenges. International Immunopharmacology, 168, 115846. https://doi.org/10.1016/j.intimp.2025.115846

Vancouver

Wang X, Li W, Liu X, Liang J, Wang L, Liu G, et al. Celastrol as a neuroprotective drug: current status and challenges. International Immunopharmacology. 2026;168:115846. doi:10.1016/j.intimp.2025.115846

BibTeX
@article{Wang2026,
  author = {Wang, Xiao and Li, Wei and Liu, Xiaoli and Liang, Jie and Wang, Luoyang and Liu, Guixian and Liu, Yi and Song, Meiying and Li, Zhen and Guo, Yuanzhen and Li, Shuai and Fu, Ningjing and Zhang, Bei},
  title = {Celastrol as a neuroprotective drug: current status and challenges},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {168},
  pages = {115846},
  doi = {10.1016/j.intimp.2025.115846}
}
Kostenlos starten →